Russell Investments Group Ltd. decreased its holdings in Icon Plc (NASDAQ:ICLR) by 22.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 97,073 shares of the medical research company’s stock after selling 28,003 shares during the period. Russell Investments Group Ltd. owned about 0.18% of Icon worth $11,458,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. Financial Gravity Companies Inc. bought a new stake in shares of Icon in the 4th quarter worth $144,000. Gotham Asset Management LLC bought a new stake in shares of Icon in the 4th quarter worth $209,000. Private Advisor Group LLC bought a new stake in shares of Icon in the 4th quarter worth $216,000. We Are One Seven LLC bought a new stake in shares of Icon in the 4th quarter worth $252,000. Finally, First National Bank of Omaha bought a new stake in shares of Icon in the 1st quarter worth $279,000. 87.11% of the stock is owned by institutional investors and hedge funds.
Icon opened at $135.46 on Monday, MarketBeat.com reports. Icon Plc has a 1 year low of $90.01 and a 1 year high of $136.93. The firm has a market capitalization of $7.33 billion, a PE ratio of 25.13, a PEG ratio of 2.13 and a beta of 0.44. The company has a current ratio of 1.85, a quick ratio of 1.85 and a debt-to-equity ratio of 0.29.
ICLR has been the subject of a number of research analyst reports. BidaskClub raised Icon from a “hold” rating to a “buy” rating in a report on Thursday, May 3rd. Zacks Investment Research upgraded Icon from a “hold” rating to a “buy” rating and set a $134.00 price target on the stock in a research note on Wednesday, April 18th. Finally, Jefferies Financial Group raised their price target on Icon to $150.00 and gave the stock a “buy” rating in a research note on Friday, June 1st. Three equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Icon currently has a consensus rating of “Buy” and an average target price of $127.82.
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.